One of the key ways Humbi AI is leveraging our data access and expertise to provide robust and timely insights to our clients is through our Rx Platform. We have access to 100% of Medicare MAPD and PDP prescription drug data, updated monthly – this, along with member month-level demographic, geographic, and eligibility data, allows a highly agile suite of suite exhibits that can be customized to each client’s specific needs with minimal ramp time. We can provide summaries of and deep dives into Rx data by prescribing physician, Dual Status, Payer Contract, or myriad additional stratifications to address a variety of business and opportunity – related questions for payers, providers, pharma manufacturers, and more.
Pictured is a sample view of brand name drug spend for Payers in New York State (2023 – emerging 2024). Likely to nobody’s surprise, Eliquis is at the top of the heap – and pharma directors everywhere likely expected to see Ozempic place highly as well, but maybe not virtually tied for second! How will that landscape continue to shift with price negotiations on the horizon, and potential payer formulary changes queued up to mitigate the effects of the CY2025 IRA provisions?
Humbi AI can offer customizable dashboards through our multi-faceted BI platform for a wide range of stakeholders, using national benchmark data or specific data received from clients. Let us know if you have a specific need – we can help your business find the answers, and sometimes that starts with finding the right questions.
